NCT06523725View on ClinicalTrials.gov

Trial Investigating the Safety and Efficacy of BRC-003 in Refractory Post-Traumatic Epilepsy

PHASE2WithdrawnINTERVENTIONAL
0
Timeline

Start Date

November 1, 2024

Primary Completion Date

April 15, 2025

Study Completion Date

April 15, 2025

Conditions
Post-traumatic Epilepsy
Interventions
DRUG

PO BRC-003 (High Cannabidiol Cannabis Extract)

The research is divided into two phases: an open-label dose-finding phase (Part A) and a subsequent randomized controlled phase (Part B).

DRUG

Placebo

Placebo

Trial Locations (1)

22601

Winchester Medical Center, Winchester

Sponsors
All Listed Sponsors
collaborator

Biopharmaceutical Research Company

UNKNOWN

lead

Dr. Paul Lyons

OTHER

NCT06523725 - Trial Investigating the Safety and Efficacy of BRC-003 in Refractory Post-Traumatic Epilepsy | Biotech Hunter | Biotech Hunter